. Annuk M, Zilmer M, Fellström B: Endothelium-dependent
vasodilation and oxidative stress in chronic renal failure: Impact on
cardiovascular disease. Kidney Int 2003; 84: 50-53
2. Foley RN, Parfrey PS: Cardiovascular disease and mortality in
ESRD. J Nephrol 1998; 11(5): 239-245
3. Cases A, Vera M, Lopez Gomez JM: Cardiovascular risk in patient
with chronic renal failure. Patients in renal replacement therapy.
Nefrologia 2002; 22: 68-74
4. Stenvinkel P: Interactions between inflammation, oxidative stress
and endothelial dysfunction in end-stage renal disease. J Ren Nutr
2003; 13(2): 144-148
5. Oygar D: Hemodiyaliz tedavisi gören hastalarda iskemik kalp
hastalığı, kalp yetmezliği ve perikarditin tedavisi. İçinde:
Süleymanlar G, Erek E (ed). Diyaliz Tedavisi. Ankara. Güneş
Kitabevi, 2004; 353-358
6. Karadayı Ergin H, Alışır S, Aksoy Z: Kronik hemodiyaliz hastaları
ile periton diyalizi hastalarının klasik koroner risk faktörleri ve
homosistein düzeyleri açısından karşılaştırılması. İstanbul Tıp
Fakültesi Mecmuası 2004; 67(2): 1-5
7. Mastalerz-Migas A, Reksa D, Pokorski M, Steciwko A, Muszyńska
A, Bunio A, Drobnik J, Pokorna-Kałwak D: Comparıson of a statin
vs. hypolipemic diet on the oxidant status in hemodialyzed patients
with chronic renal failure. J Physiol Pharmacol 2007; 58: 363-370
8. Perunicic-Pekovic GB, Pliesa SI, Rasic ZR, Stankovic SD, Ilic MN:
Inflammatory markers, nutritional paremeters and polyunsaturated
fatty acids in hemodialysis patients. Med Pregl 2007; 60: 43-47
9. Rubanyi GM: The role of endothelium in cardiovascular homeostasis
and diseases. J Cardiovasc Pharmacol 1993; 22: 1-14
10. Önder MR, Barutcuoğlu B. İçinde: Önder MR, Barutcuoğlu B (ed).
Endotel Dergisi 2005; Ocak: 9-17
11. Borawski J, Naumnik B, Pawlak K, Mysliwiec M: Endothelial
dysfunction marker von Willebrand factor antigen in hemodialysis
patients: Associations with pre-dialysis blood pressure and the acute
phase response. Nephrol Dial Transplant 2001; 16: 1442-1447
12. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn
FJ, Ball S, Townend JN, Baigent C: Inflammation, endothelial
dysfunction and platelet activation in patients with chronic kidney
disease: The chronic renal impairment in Birmingham (CRIB)
study. Am J Kidney Dis 2004; 43: 244-253
13. Sniderman AD, Solhpour A, Williams K, Sloand JA: Cardiovascular
death in dialysis patients: Lessons we can learn from AURORA.
Clin J Am Soc Nephrol 2010; 5: 335-340
14. Chan KE, Thadhani R, Lazarus JM, Hakim RM: Modeling the
4D Study: Statins and cardiovascular outcomes in long-term
hemodialysis patients with diabetes. Clin J Am Soc Nephrol 2010;
5: 856-866
15. Campese VM, Park J: HMG-CoA reductase inhibitors and the
kidney. Kidney Int 2007; 71(12): 1215-1222
155
Özkurt S et al : Evaluation of Pleiotropic Effects of Statins in
Chronic Renal Failure Patients
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Turk Neph Dial Transpl 2011; 20 (2): 150-155
16. Navarro JF, Mora C, Muro M, Garcia-Idoate G: Effects of
atorvastatin on lipid profile and non traditional cardiovascular risk
factors in diabetic patients on hemodialysis. Nephron Clin Pract
2003; 95(4): 125-135
17. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-
Ciocca C: Effects of atorvastatin on Lp(a) and lipoprotein profiles
in hemodialysis patients. Ann Pharmacother 2008; 42(1): 9-15
18. Davignon J, Jacob RF, Mason RP: The antioxidant effect of statins.
Coron Artery Dis 2004; 15(5): 251-258
19. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ,
Stalenhoef AF, van Leusen R: Atorvastatin and simvastatin in
patients on hemodialysis:effects on lipoproteins, C-reactive protein
and in vivo oxidized LDL. J Nephrol 2003; 16(2): 238-244
20. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana
S: Serum malondialdehyde and prevalent cardiovascular disease in
hemodialysis. Kidney Int 1999; 56:1078-1083
21. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino
H, Chiong M, Bustos C, Garcia L, Mellado R, Vukasovic JL, Godoy
I, Lavandero S: Pleiotropic effects of atorvastatin in heart failure:
Role in oxidative stres,inflammation, endothelial function and
exercise capacity. J Heart Lung Transplant 2008; 27(4): 435-441
22. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects
of simvastatin on high-sensitivity C-reactive protein and serum
albumin in hemodialysis patients. Am J Kidney Dis 2002; 39(6):
1213-1217
23. Mason RP, Walter MF, Jacob RF: Effects of HMG-CoA reductase
inhibitors on endothelial function: Role of microdomains and
oxidative stres. Circulation 2004; 109: 1134-1141
24. Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M:
Effects of fluvastatin on homocysteine and serum lipids in kidney
allograft recipiens. Ann Transplant 2002; 7(1): 52-54
25. Dejanov P, Polenaković M, Oncevski A, Sikole A, Dejanova B,
Panov S, Kostovska S: The role of the Von Willebrand factor in
Renal diseases and hemodialysis patients. Prilozi 2004; 25(1-2):
5-15
26. Tekin A, Tekin G, Guzelsoy D, Kaya A, Gurel CV, Yigit Z, Ulutin
T: Effect of atorvastatin (10 mg) on hemostatic and ınflammatory
parameters in hyperlipidemic patients with angiographically proven
coronary artery disease. Am J Cardiol 2004; 94: 206-209
27. Asberg A, Hartmann A, Fjeldsa E, Holdaas H: Atorvastatin improves
endothelial function in renal-transplant recipients. Nephron Dial
Transplant 2001; 16: 1920-1924
28. Kaysen GA: The microinflammatory state in uremia: Causes and
potential consequences. J Am Soc Nephrol 2001; 12(7): 1549-1557
29. İkejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo
T, Taira T, Adachi M: Effects of atorvastatin on triglyceride-rich
lipoproteins, low-density lipoprotein subclass, and C-reactive protein
in hemodialysis patients. Metabolism 2004; 53(9): 1113-1117
30. Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-
Campderá F, Vega A, Abad S, Luño J: Effects of atorvastatin on
inflammatory and fibrinolytic parameters in patients with chronic
kidney disease. J Am Soc Nephrol 2006; 17: 231-235
31. Li JJ, Chen XJ: Simvastatin inhibits interleukin-6 release in human
monocytes stimulated by C-reactive protein and lipopolysaccharide.
Coron Artery Dis 2003; 14(4): 329-334
32. Kadikoylu G, Yukselen V, Yavasoglu, Bolaman Z: Hemostatic
effects of atorvastatin versus simvastatin. Ann Pharmacother 2003;
37: 478-484
Thank you for copying data from http://www.arastirmax.com
